Mai 2017

CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017

Basel, Switzerland, May 4th 2017 -- CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma ADC drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide array of anti-tumor agents directly to [...]

Dezember 2016

CIS Pharma appoints Dr. Christophe Thommen as new head of research and laboratory operations

Bubendorf, Switzerland, December 2016 -- CIS Pharma welcomes Dr. Christophe Thommen, who will lead the research team as the new head of research and laboratory operations. Christophe is an expert in natural products chemistry and his expertise has already led to a number of innovative and efficient syntheses in the industry. With his focus on scalability and industrialization of synthesis [...]

Oktober 2016

CIS Pharma’s solubilization technology comprising cyclosporine A has entered proof of concept phase

Bubendorf, Switzerland October 2016 - CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates water-soluble formulations for a number of model drugs such as cyclosporine A. The technology can be applied to a large number of water-insoluble drugs, improving the bioavailability and tolerance for drugs used [...]

September 2016

CIS Pharma has successfully concluded the development of novel contact lens coating technology

Bubendorf, Switzerland, September 2016 -- CIS Pharma has concluded the development of a novel contact lens coating technology based on the Cellophil® Smart Polymer platform. The technology has been shown to increase surface wettability and lubricity and is expected to increase the wear comfort of silicone hydrogel contact lenses. CIS Pharma has created novel bio-inspired polymer derivatives based on its [...]

August 2016

CIS Pharma to launch new web presence

Bubendorf, Switzerland, August 2016 -- CIS Pharma’s new company website is online. The site was established in collaboration with SKYWEB, a fast-growing start-up incorporated in close proximity to CIS Pharma. The new web presence supports the mobile lifestyle of customers and offers an overview of our projects. For questions relating to our technology portfolio, please feel free to call us [...]

Juni 2016

CIS Pharma has developed contact lens care products based on its new patented technology platform

Bubendorf, Switzerland, June 2016 -- CIS Pharma has developed a novel multipurpose solution for contact lenses. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team has developed the next generation contact lens care solution that increases contact lens wear comfort while keeping the efficacy of [...]

Januar 2016

CIS Pharma announces the first milestones in its ADC research program are achieved

Bubendorf, Switzerland, January 2016 -- Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers were evaluated for loading the drug carrier with anti-cancer moieties. CIS Pharma has successfully loaded its proprietary Cellophil® Smart Polymer drug carriers with model compounds for cancer therapies. CIS Pharma engineers the ADCs [...]

November 2015

CIS Pharma creates novel contact lens coating technology

Bubendorf, Switzerland, November 2015 -- CIS Pharma is expanding its Cellophil® Smart Polymer platform with new bio-inspired derivatives. The derivatives are used as building blocks for the development of a novel contact lens coating technology. The Cellophil® Smart Polymer coating technology aims to improve the wettability of silicone hydrogel contact lenses. In addition, the coating is designed to prevent the [...]

September 2015

CIS Pharma develops solubilization technology for hydrophobic drugs

Bubendorf, Switzerland, September 2015 -- CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The approach comprises a polymer-based solubilization technology that can be applied to a large number of water-insoluble drugs. The technology aims to improve the bioavailability and tolerance for drugs used in various indications [...]

Juni 2015

CIS Pharma creates next generation contact lens care products

Bubendorf, Switzerland, June 2015 -- CIS Pharma is investigating novel formulations and combinations of active ingredients to improve contact lens care. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team is targeting a novel concept that allows for higher contact lens wear comfort while keeping [...]

April 2015

CIS Pharma appoints Davide Panighetti to its cancer research team

Bubendorf, Switzerland, April 2015 -- CIS Pharma welcomes Davide Panighetti, who reinforces the research team as the new synthesis chemist. Davide’s skills will boost the team working on proprietary drug carriers developed for antibody-drug conjugates. The drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide [...]

Januar 2015

CIS Pharma to develop drug carriers for ADCs

Bubendorf, Switzerland, January 2015 -- CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared to current [...]